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Abstract 
Aims: To evaluate the accuracy of sentinel lymph node biopsy in breast cancer patients at this institution, using combined technetium-
99m (
99mTc) sulphur colloid and patent blue vital dye. 
Methods: From March 2007 to July 2008, 50 patients with a tumour of less than 3 cm and with clinically negative axillary lymph nodes 
underwent sentinel lymph node biopsy (SLNB), followed by axillary lymph node dissection (ALND). Sub-areolar 
99mTc sulphur colloid 
injection was performed the day before surgery, and patent blue vital dye was also injected sub-areolarly at least 5 minutes before 
surgery. Sentinel lymph node was identified during the surgical procedure, using a gamma probe and direct vision. All sentinel nodes 
underwent frozen section analysis. Later haematoxylin and eosin staining and immunohistochemical analysis were performed. Finally, 
SLNB was compared with standard ALND for its ability to accurately reflect the final pathological status of the axillary nodes. 
Results: The sentinel lymph node (SLN) was identified in 48 of 50 patients (96%). The number of sentinel lymph nodes ranged from one 
to four (mean 1.48) and non-sentinel nodes ranged from seven to 27 (mean 14.33). Of the 48 patients with successfully identified SLNs, 
29.17% (14/48) were histologically positive. Sensivity of the SLN to predict axilla was 93.75%; accuracy was 97.96%. The SLN was 
falsely negative in one patient—6.25% (1/16). 
Conclusions: The SLNB represents a major advance in the surgical treatment of breast cancer as a minimally invasive procedure 
predicting the axillary lymph node status. This validation study demonstrates the accuracy of the SLNB and its reasonable false negative 
rate when performed in our institute. It can now be used as the standard method of staging in patients with early breast cancer at this 
institution. 
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Introduction 
Breast cancer is the most common malignancy among women 
in Europe, accounting for 20% or more of all cancers and 
representing the leading cause of cancer deaths in females 
between 35 and 55 years old in Europe. About one in 12 will 
develop the disease before the age of 75 years, representing a 
lifetime risk around 8% [1,2]. It is important that effective 
screening methods and accurate ways for staging and 
prognosis once the diagnosis has been established are 
available [3,4]. Axillary lymph node dissection (ALND) provides 
information about disease stage, local control of disease, and 
helps in the decision making for adjuvant therapy [5–7]. 
However, for patients with pathologically negative lymph nodes 
survival rates are not increased by ALND [8], and there are a 
considerable number of related complications, such as sensory 
nerve damage, haemorrhaging, seroma formation (20–55% of 
cases) [9,10] and chronic lymphoedema of the arm (7–56%) 
[11,12]. 
As about 60–70% of patients with early breast cancer have no 
regional axillary lymph node metastasis [12], sentinel lymph 
node biopsy (SLNB) is an easy to establish, ideal alternative, 
capable of accurately predicting the state of axillary lymph 
nodes, avoiding classical axillary lymph node staging and its 
consequent morbidity. 
After being first described by Cabanas et al in 1977 [50], for 
carcinoma of the penis, the SLNB technique was then used in 
staging malignant melanoma, as reported in 1992, by Morton et 
al [13], and more recently for breast carcinoma as reported by 
Krag  et al in 1993 [14] and Giuliano et al in 1994 [15]. The 
SLNB serves as a stand alone method for determining axillary 
nodal status, providing physicians with the ability to distinguish 
positive axillary lymph nodes in a relatively simple, safe, rational 
and accurate fashion. 
The sentinel lymph node (SLN) is the first lymph node to drain 
the entire lymphatics of the breast. Since metastatic breast 
cancer cells travel via this route, an SLN free of metastatic 
cancer predicts the status of the remaining axillary nodes as 
also negative for metastasis [16,17]. 
Over the past 14 years, sentinel node biopsy in breast cancer 
patients has become an exciting research topic. Many studies 
have shown that SLNB accurately predicts axillary lymph node 
status [18–20] and is associated with less morbidity than ALND 
completion [9,21,22]. Results from international breast cancer 
centres show that, with the use of optimal techniques, SLNB 
predicts axillary nodal status with high accuracy and low clinical 
false-negative rates [20,23–26]. Many medical centres adopted 
SLNB without completion of ALND in patients who have a 
clinical negative SLN, in an effort to decrease the morbidity of 
axillary lymphoadenectomy while maintaining accurate staging 
[27,28]. 
The purpose of this study was to evaluate the accuracy of SLNB 
at this institution and to thereafter implement it as the standard 
method of staging in patients with early breast cancer. 
Using radiolabelled nanocolloid and patent blue vital dye as 
tracers, SLNB was performed in patients with breast cancer and 
its feasibility evaluated for patients in our institution. 
 
Patients 
Fifty consecutive breast cancer patients, with a primary tumour 
less than 3 cm and a clinically negative axilla, were included in 
a prospective study performed between March 2007 and July 
2008 at our hospital. Both mastectomy and breast conservation 
patients were equally eligible. All patients undergoing the study 
gave their informed consent for sub-areolar injection of 
radiotracer and patent blue vital dye and for the surgical 
procedure to be performed. The trial was approved by the 
institutional review board. The age of the patients ranged from 
36 to 79 years, with a mean age of 59.4 years. All patients 
underwent SLNB and consecutive axillary dissection. Used 
inclusion and exclusion criteria are listed in Table 1. 
 
Methods 
During study enrolment at our institution, the SLNB technique 
included the use of technetium-99m (
99mTc) sulphur colloid and 
blue dye. The 
99mTc sulphur colloid was prepared by the nuclear 
medicine departments of two other validated institutions with 
which our hospital has an agreement (Hospital CUF 
Descobertas  and  NuclearMed—Instituto de Medicina 
Nuclear), and comprised a solution containing 1.0mCi (1.0mCi 
= 37MBq) 
99mTc labelled rhenium sulphide colloid (nanocolloid 
particles < 80 nm—Nanocis®). A total volume of 0.4 ml was 
injected sub-areolarly 15–24 hours before the operation. Planar 
scans of the involved breast and axillary area, in anterior and 
lateral projections, were acquired 15–30 minutes and 3 hours 
after tracer injection, to ascertain the overall distribution of the
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Table 1: Inclusion and exclusion criteria 
radiotracer and identify SLN. A skin mark was made over the 
first spot to become hot to facilitate SLN location during the 
operation. 
With the patient already anaesthesiated, and at least five 
minutes before surgery, blue dye (Bleu Patente V Sodique 
Guerbet
® 2.5%) was injected sub-areolarly in four deposits 
around the nipple totalling 2 ml. The patient was then prepped 
and draped in the usual sterile fashion. A low-transverse axillary 
incision was made, and a handheld gamma probe (Neo2000
® 
Gamma Detection System, Neoprobe Corp., OH, USA) was 
used to guide the dissection for hot-spot detection. A hot spot 
was defined as the spot that had the greatest radioactivity 
counts in the lymphatic basin, which was at least 25 counts per 
ten seconds or greater. All 'hot' nodes and blue nodes were 
removed. After removing all nodes, the activity of the resection 
bed was assessed and should be less than 10% of the hottest, 
most radioactive excised lymph node. The SLN specimen was 
sent for frozen section analysis, and regardless of the result, all 
patients underwent ALND. 
 
Pathological examination 
All blue and 'hot' SLN specimens were carefully identified and 
evaluated by a pathologist. All lymph nodes in the specimen 
were identified and dissected from the surrounding tissue by the 
pathologist. The number of nodes and their dimensions were 
accessed. SLNs smaller than 10 mm did not undergo frozen 
section analysis, SLNs ≤ 5 mm were processed and totally 
included in paraffin blocks (one block with all SLNs ≤ 5 mm), 
SLNs > 5 mm and < 10 mm were sectioned ± 2/3 mm 
perpendicularly to the longitudinal axis, processed and totally 
included in paraffin (one block per SLN > 5 and < 10 mm) and 
SLNs ≥ 10 mm underwent frozen section analysis. SLNs > 10 
mm were longitudinally bisected and one of the half sections 
was submitted to frozen section analysis (one to three frozen 
sections per analysis) and/or cytological analysis (imprint). 
Those not subjected to frozen sectioning were then processed 
and totally included in paraffin (two blocks per SLN ≥ 10 mm). 
All SLNs were sectioned (100 µm sections) and every other 
section (first, third, fifth, seventh, etc.) stained with haematoxylin 
and eosin (H&E). The corresponding section (second, fourth, 
sixth, eight, etc.) was stained immunohistochemically, using a 
cytokeratin cocktail of monoclonal antibodies that recognize a 
wide range of high- and low-molecular weight keratin peptides 
(AE1/AE3, Dako
®). Both SLNs and non-nodal tissue collected 
from ALND were sectioned and examined for the presence of 
tumour cells. 
Statistical analysis 
Important data, including patient demographics and tumour 
characteristics, were recorded in a Microsoft® Office Excel 
spreadsheet. 
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Table 2: Patient clinical characteristics (n=50) 
 
Table 3: Disease characteristics (n=50) 
Accuracy was defined as the percentage of patients in which 
the sentinel node status has accurately represented the lymph 
node status of patient. False negative (FN) rate was defined as 
the percentage of patients who had histologically negative SLNs 
but other positive axillary nodes. Fisher's exact test and χ
2 tests 
were used to analyse the impact of different factors on this 
method. 
Results 
A total of 50 consenting patients were enrolled in the study. The 
clinical data of the patients and their disease characteristics are 
shown in Tables 2 and 3. All the 50 patients who underwent 
lymphoscintigraphy had lymphatic drainage towards the axilla. 
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Table 4: Summary of sentinel node biopsy  
 
 
Figure 1: Summary of results.
Breast surgery consisted of mastectomy in 17 patients (34%) 
and breast conservative surgery in 33 patients (66%). The 
average primary tumour size in the study population was 1.9 
cm, ranging from 0.6 to 4.0 cm, including 36 T1 tumours (72%) 
and 14 T2 tumours (28%). There was only one tumour of more 
than 3 cm after pathological examination. As for histological 
features, there were 42 infiltrating ductal cancers (84%), two 
infiltrating lobular cancers (4%), one mixed carcinoma (2%), two 
papillary invasive carcinomas (4%), one micropapillary invasive 
carcinoma (2%) and two mucinous carcinomas (4%). 
The SLN was successfully detected in 48 of the 50 patients, 
corresponding to a surgical overall identification rate of 96% 
using both dye and radioisotope, not statistically different to 
other equivalent studies. The patients in which detection was 
not accomplished were 57 and 76 years old, with a tumour size 
of 15 and 16 mm, respectively, both in the lateral superior 
quadrant location. 
In the 48 successful cases, the number of nodes detected 
ranged from one to four, and the mean number of sentinel 
lymph nodes per case was 1.48. All SLNs were located at level 
1 of the axilla. The number of dissected non-sentinel lymph 
nodes ranged from seven to 25, with a total of 688 nodes and a 
mean of 14.33 nodes/case. 
A total of 14 patients (29.17%) had SLN positive for metastasis 
by definitive histological analysis, two of which were micro-
metastasis (< 2 mm), not detected by frozen section analysis. 
Only 25% of cases with T1 lesions were found to have axillary 
lymph node metastasis compared to 42.86% of cases with T2 
lesions. SLN analysis was negative in 34 patients (70.83%); 
however, metastatic cells were found in two lymph nodes of one 
patient after axillary dissection, accounting for the only FN result 
(FN rate 6.25% (1/16)), (Figure 1 and Table 4). 
The FN finding occurred in a 79-year-old woman with a 28-mm 
ductal invasive carcinoma located in the medial superior 
quadrant of the breast. 
These data give us a sensivity of 93.75%, a specificity of 100%, 
a positive predictive value of 100% and a negative predictive 
value of 97.06%, with an overall accuracy of 97.96% for 
predicting the malignant status of the axilla. 
In five cases, the SLN was the only positive node, four of which 
had a ductal invasive tumour histological type and one had a 
micropapillary invasive pattern. 
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Table 5: Identification and false-negative rates from similar sentinel lymph node biopsy studies 
Our detection rate reached 100% after six SLNB procedures, 
and our FN occurred at the 15th procedure. 
 
Discussion 
The SLN is the first lymph node to receive the lymphatic 
drainage of a metastatic tumour. In theory, there is a spread of 
tumour cells from sentinel nodes to other nodes. If so, further 
spread of cancer cells can be predicted by the SLNs [13,14]. 
The SLNB procedure in breast cancer patients is already a 
regular procedure in western countries. 
The purpose of this study was to prospectively evaluate the 
accuracy of the SLNB in patients with early stage breast cancer 
undergoing this procedure by surgeons at this institution, with 
completion of ALND for confirmation. 
Current literature frequently mentions that an identification rate 
greater than 90% and a FN rate of no more than 5–10% is a 
reasonable goal for surgeons and institutions developing the 
SLNB technique [29]. The accuracy of SLNs to predict axillary 
status should ideally be greater than 95%. 
The identification rate in this study, using sub-areolar injections 
of dye/tracer, is 96%. The first study of Giuliano et al reported a 
65% identification rate with blue dye [15], and their more recent 
studies achieve an identification rate of 93% and 99% of cases 
[30,31]. 
Our detection failures occurred in the first and sixth cases, 
gradually improving thereafter the dissection and identification 
of the SLN specimen. An identification rate of 100% in the later 
cases of our study reflects the plateau of the learning curve for 
this technique [32]. Some studies have indicated that the 
success rate is lower in patients older than 50 years [33], which 
is in accordance with our results. 
Some reports suggest that the radiotracer and the blue dye are 
complementary, facilitating SLN detection when used together, 
thus accelerating the learning curve [34–36]. 
Despite controversy, we adopted the sub-areolar site for blue 
dye and radiotracer injection based on the hypothesis that 
breast drains lymph as a single unit, due to its embryological 
development from ectodermal primitive milk streak that 
becomes the areolar complex, there is also some evidence of 
high SLN identification rate and low FN rates and a rapid 
learning curve using this site of injection [37]. 
The FN rate is of great importance, especially as the true 
axillary nodal status has prognostic value and that this 
procedure is to be applied as a treatment protocol. In our study, 
the observed FN rate was 6.25%, not statistically different to 
other equivalent studies. Several series showed that FN SLNs 
occurred in tumours larger than 15 mm [34,38]. In this study, the 
false-negative SLN occurred in a 28-mm tumour. 
In our study, the identification rate and FN rate are similar to 
other preliminary studies that used radiotracer and blue dye 
(Table 5). 
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Table 6: Comparison of this study with Cody's meta-analysis and ALMANAC's multi-centre study  
Barnwell et al [40] assessed the success and accuracy of SLNB 
with blue dye and 
99mTc sulphur colloid compared to ALND. SLN 
was found in 38 of the 42 (90%) cases with no FNs. In a study 
by Nwriaku et al [18], using both blue dye and radiotracer, 119 
women with breast carcinoma who underwent SLN and ALND, 
the SLN identification rate was 81% with one FN in a patient 
with axillary disease (FN rate of 4%). Mertz et al [42] analysed 
the relevance of the sub-areolar injection for SLN detection in 
multiple foci breast cancer, comparing 79 breast cancer patients 
who underwent 
99mTc filtered sulphur colloid sub-areolar 
injection (group I) with 32 patients who underwent peritumoural 
injection (group II). SLN was detected in 97.9% and 96.9% of 
the cases, respectively. No FNs were observed in group I and 
one FN in group II (FN rate 10%), which was related to a cancer 
with histological multiple invasive foci. Borgstein et al [43] 
performed periareolar injection of blue dye and peritumoural 
radioisotope in 130 patients and achieved a 96.9% identification 
rate and a 0% FN rate. Smith et al [44] compared 19 patients 
who received 
99mTc sub-areolar and peritumoural blue dye 
injections with 19 patients who received peritumoural injection 
of both blue dye and radiotracer. SLNs were found in all 
patients of the first group and in 18 patients of the second 
group. The FN rate was 0% for the first group and 20% for the 
second group. McMasters et al [36] documented a 98.8% 
identification rate and a 5.9% FN rate, using sub-areolar 
radiotracer injection and peritumoural blue dye injection in 85 
patients. Donahue [45] obtained an identification rate of 100% 
and a FN rate of 8.3%, using peritumoural radioisotope and 
sub-areolar blue dye injection in 42 patients. Kern [46] reported 
an identification rate of 98.4%, a FN rate of 0% and an accuracy 
of 100% for predicting the malignant status of the axilla in a 
study with 187 patients, using sub-areolar injection dual-tracer 
technique. Chapgar et al [47], reported a multi-centre clinical 
trial on 3961 patients. For 1762 patients given radiotracer 
injection, identification rates of 91.1% for peritumoural 
injections, 99.3% for sub-areolar injections and 95.6% for 
periareolar injections were obtained, with FN rates between 8%
and 9%. D'Eredita et al [37] achieved high SLN identification 
rates (94.2–100%) but with FN rates of 9% in their first study, 
but this dropped to 0% in later studies, showing clearly the 
importance an adequate learning period, also sustained by 
Cody et al [48]. 
Our results are also similar to reports based on larger sample 
series such as Cody's [29] meta-analysis of 12 validation 
studies from 1993 to 1999 and ALMANAC Trialists Group's [49] 
prospective multi-centre validation study performed to quantify 
identification and FN rates of SLNB and evaluate factors 
influencing them, both using radiotracer and blue dye (Table 6) 
[29, 49]. 
All these studies demonstrate that SLNB can accurately predict 
the axillary lymph node status. The FN results suggest that a 
correct inspection of the axilla and removal of any nodes that 
appear abnormal is an important part of the SLN procedure. 
 
Conclusion 
Sentinel lymph node biopsy is considered to be the gold-
standard method in staging patients with early-stage breast 
cancer and a clinically negative axilla, providing important 
prognostic information to plan adjuvant treatment and avoiding 
the morbidity of invasive ALND. 
The present study reflects our experience, indicating that the 
SLNB can be performed in an accurate, safe and reproducible 
manner in our hospital and is now ready to be adopted as the 
standard staging procedure for patients with early breast 
cancer. 
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